Figure 3.

TNF-α (A,C) and IL-6 (B,D) levels in the BAL fluid of (A,B) mice treated intranasally with vehicle (veh; n = 18), LPS (20 μg per mouse; n = 17), PGE₂ (20 μg per mouse) concomitantly with LPS (n = 22) or pretreated with the EP₄ receptor antagonists GW627368X (GW; 10 mg·kg⁻¹ s.c.; n = 8) or ONO AE3-208 (10 mg·kg⁻¹ s.c.; n = 5) 30 min before intranasal LPS or LPS concomitantly applied with PGE₂ (n = 6 or 10 respectively). (C,D) Intranasal application of vehicle (veh, n = 8) or LPS (20 μg per mouse, n = 11) alone or in combination with the EP₄ receptor agonist ONO AE1-329 (n = 3–10). Each point shows the cytokine concentration (ng mL⁻¹) from one animal. Data were analysed using one-way anova and multiple comparisons were calculated with Tukey’s post test. *P < 0.05, **P < 0.01, ***P < 0.001.